FRM
GLUE icon

Fox Run Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Fox Run Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$360K Buy
+14,883
New +$281K 0.06% 611
2025
Q2 		– Sell
-27,394
Closed -$127K – 999
2025
Q1 		$127K Buy
+27,394
New +$168K 0.02% 848

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fox Run Management's GLUE Position: Q2 2026 in Review

Fox Run Management opened a new position in Monte Rosa Therapeutics (GLUE) in Q2 2026: 14,883 shares worth $360K. The stake represents 0.06% of the portfolio and ranks #611 among its holdings. This is a return to the name: Fox Run Management previously reported a position in GLUE as recently as Q1 2025.

Fox Run Management first reported a position in GLUE in Q1 2025 and has held it in 2 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Fox Run Management held 14,883 shares of Monte Rosa Therapeutics worth $360K as of Q2 2026.
  • Monte Rosa Therapeutics was a new Fox Run Management position in Q2 2026.
  • Monte Rosa Therapeutics made up 0.06% of Fox Run Management's portfolio in Q2 2026, its #611 holding.
  • Fox Run Management first reported a position in Monte Rosa Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.